HIV & Hepatitis A, B, and C

Hepatitis A, B, and C share part of a name, but they are different viruses. Knowing which one a test or vaccine refers to can turn a confusing appointment into a clearer plan.

Start here: one name, three different infections

Hepatitis means inflammation of the liver. Hepatitis A, B, and C are three viruses that can cause it; the letters do not describe stages of one disease, and having one does not mean you have the others. ¹⁴

“Acute” means a recent or short-term infection. “Chronic” means an infection that persists. A person can have chronic hepatitis without noticeable symptoms, so feeling well is not a substitute for testing. ¹

Use this as an orientation, not a way to diagnose yourself. Blood tests and a discussion of your health history are what distinguish these infections and guide the next step. ¹

Why hepatitis belongs in HIV care

People living with both HIV and chronic hepatitis B or C can develop liver complications more quickly than people with hepatitis alone. That is a reason to connect care early, not a prediction about any one person's future. ²³

There is practical good news: hepatitis C treatment works very well in people living with HIV, and some HIV medications also treat hepatitis B. The important part is choosing compatible medications and following through on testing and monitoring. ³²

Your HIV viral-load result does not tell you your hepatitis status. HIV, hepatitis B, and hepatitis C require their own tests; an undetectable HIV result should not be read as “all hepatitis tests are negative.” ²⁹¹⁰

For HIV itself, achieving and maintaining an undetectable viral load means you do not transmit HIV through sex: U=U. That remains true when discussing liver health, and it does not replace the separate work of hepatitis vaccination, testing, and treatment. ¹¹⁵

Hepatitis A: prevent it, and act quickly after exposure

Hepatitis A can spread through contaminated food or water and close personal contact, including sexual contact. You do not have to travel to acquire it, and its transmission is not a measure of someone's cleanliness or worth. ¹

Most people recover without lasting liver damage, and hepatitis A does not become chronic. It can nevertheless cause serious illness, especially in people who already have liver disease. ⁶⁵

For people living with HIV who are not immune, hepatitis A vaccination is recommended. The HIV-specific guidance also recommends checking the antibody response after the series, because receiving doses and developing adequate protection are not always the same thing. ¹²

If you learn that you had close contact with someone with hepatitis A, call a clinician promptly rather than waiting for symptoms. Preventive treatment is time-sensitive: for people with HIV who are not immune, NIH recommends hepatitis A vaccine together with immune globulin within two weeks of exposure. Immune globulin provides ready-made antibodies for short-term protection. ¹²⁶

Do not substitute a combined A/B vaccine on your own for post-exposure care. CDC specifically states that Twinrix, the combined vaccine, is not recommended for hepatitis A post-exposure prevention. ⁶

Hepatitis B: testing and treatment need to fit your HIV regimen

Hepatitis B can spread through blood and other body fluids, including during sex and sharing injection equipment. A recent infection may resolve, but some infections become chronic and need continuing care. ¹⁵

The useful first question is not simply “Was my hepatitis test negative?” Ask whether you had the hepatitis B triple panel, which looks at three different markers. Together, they help a clinician distinguish current infection, past infection, vaccine-related immunity, and a need for vaccination. ⁹

Some combinations need more testing rather than a simple yes-or-no label. Ask your clinician to explain the whole panel; a single antibody result should not be interpreted in isolation. ⁹

For people living with both HIV and chronic hepatitis B, NIH recommends an HIV treatment plan that also treats hepatitis B. Usually this includes tenofovir plus emtricitabine or lamivudine as part of a complete HIV regimen; alternatives require a clinician's assessment. This is not a medication-switching instruction. ²

Current hepatitis B treatment is generally control rather than cure. Follow-up can include hepatitis B viral-load testing, liver tests, and assessment of whether liver-cancer surveillance is needed. An undetectable hepatitis B viral load does not mean every future liver risk has disappeared. ²⁷

Hepatitis C: a cure is possible, including when you have HIV

Hepatitis C is mainly a bloodborne infection. Sharing needles, syringes, or other injection equipment can transmit it; sexual transmission also occurs, including among some people living with HIV. It is not spread through hugging, sharing food, or ordinary social contact. ⁴⁵

Modern treatment uses oral medicines called direct-acting antivirals, often shortened to DAAs. CDC reports that these medicines cure more than 95% of cases, usually with 8–12 weeks of treatment; the actual regimen and duration depend on a person's medical history. ⁸

Living with HIV is not a reason to assume treatment will fail. Specialist guidance reports similar treatment effectiveness and adverse-event rates in people with and without HIV when appropriate DAA regimens are used. ³

An antibody result is not the same as a current infection

The first test commonly checks for hepatitis C antibodies, which show that your immune system has encountered the virus. A reactive result needs an HCV RNA test, which looks for the virus itself and tells the care team whether there is a current infection. ¹⁰

Ask for automatic follow-up RNA testing, sometimes called “reflex testing,” after a reactive antibody result. CDC recommends collecting what is needed in one visit when possible, reducing the chance that a second test never happens. ¹⁰

After a very recent exposure, an antibody test may still be negative. Tell the clinician when the exposure happened, because RNA testing may be appropriate even when antibodies have not appeared. ¹⁰

What “cured” means, and what it does not mean

The standard confirmation of cure is an undetectable or nonquantifiable HCV RNA result 12 or more weeks after treatment is finished. This is called a sustained virologic response, or SVR12; it is not simply a negative result while taking medication. Current specialist guidance also allows an earlier, four-week assessment for selected people without cirrhosis or prior DAA treatment who may face barriers to completing the 12-week assessment, so confirm the plan with your clinician. ¹³

A hepatitis C antibody test may remain positive after cure. If there is a new exposure or concern about reinfection, the useful test is HCV RNA, not another antibody test alone. ¹³

Cure does not create immunity, and there is no hepatitis C vaccine. You can acquire hepatitis C again, so access to sterile equipment, prevention support, and repeat RNA testing when indicated remains important. ⁸¹³

If you already have cirrhosis, meaning advanced liver scarring, curing hepatitis C does not end liver-cancer surveillance. Specialist guidance recommends continuing surveillance every six months, generally with ultrasound, with or without an additional blood test. People without cirrhosis do not automatically need that same schedule. ¹³

Liver scarring: what the assessment is for

“Fibrosis” means liver scarring. Before hepatitis C treatment, the care team assesses whether you have advanced scarring or cirrhosis, because that affects treatment choices and the follow-up you need after cure. A liver biopsy is not automatically necessary. ¹⁴

The assessment may combine blood-test calculations, such as FIB-4 or APRI, with a scan that measures liver stiffness, called elastography. These tests have limits: one reassuring result does not always rule out significant scarring, and conflicting results may need further assessment. Ask what your results mean together rather than interpreting a single number yourself. ¹⁴

Feeling well, having normal liver enzymes, or having a low hepatitis C viral load does not reliably tell you how much scarring is present. Treatment should not be delayed simply to wait for liver damage to become worse. ¹⁴

Treatment and harm reduction belong together

Current or recent injection drug use should not, by itself, exclude someone from hepatitis C treatment. Specialist guidance supports treatment alongside services that reduce harm and help people stay connected to care; requiring proof of abstinence creates a barrier rather than identifying who can benefit. ¹⁴

Ask about sterile needles, syringes, and other injection equipment, and support for substance use if you want it. Hepatitis C reinfection is a reason for testing and care, not blame. If exposure risk continues after cure, your care team may recommend at least annual HCV RNA testing; another antibody test alone cannot diagnose reinfection. ¹⁴¹³

HIV PrEP and HIV PEP are not substitutes for hepatitis C prevention. They address HIV; hepatitis C prevention still includes reducing blood exposure and access to testing and treatment. ¹⁵⁴

Getting treatment, including in Florida

If cost or a coverage decision is delaying treatment, ask the clinic or pharmacy who can help with the next step. Useful questions include: Does this prescription need prior authorization? What exactly was denied? Can the clinician appeal? Is there an assistance program I may qualify for? What will visits, tests, and medication each cost?

You do not need to solve every part alone. In Florida, start with your existing HIV care team or use our care locator and assistance hub to look for help. Confirm services, eligibility, and costs directly; a listing is not a promise that a particular clinic has appointments or that a program will cover every charge.

Before leaving a visit, ask who will coordinate the prescription, medication-interaction review, liver assessment, and cure-confirmation test. A clear plan matters more than being handed several unconnected referrals.

Vaccines: review protection, not just the number of shots

For adults living with HIV, the plan should include checking immunity to hepatitis A and B and offering vaccination when needed. Neither vaccine prevents hepatitis C, and a hepatitis C cure does not protect against hepatitis A or B. ²¹²¹

HIV-specific guidance recommends antibody testing about one to two months after completing either vaccine series. Some people need additional doses or a different series if the response is inadequate; that is a reason to adjust the plan, not a personal failure. ¹²

There are separate A and B vaccines and a combined A/B option. The product and schedule should fit your prior doses, test results, and clinical situation; an adult HIV vaccine schedule should not be guessed from a general childhood vaccine chart. ¹²

Some HIV medications reduce the chance of acquiring hepatitis B, but they do not eliminate it. NIH recommends hepatitis B vaccination for people who need it even when their HIV regimen includes hepatitis B-active drugs. ¹²

Make one medication plan, not several disconnected ones

Before hepatitis C treatment, bring a complete medication list: HIV medicines, prescriptions from other clinicians, over-the-counter products, vitamins, and supplements. The hepatitis C and HIV teams need to check interactions before choosing a regimen. ³⁸

Do not pause HIV treatment to make room for hepatitis C treatment. Specialist guidance explicitly recommends against interrupting ART for that purpose; if a change is needed, it should be planned with the HIV clinician. ³

Hepatitis B testing matters before hepatitis C treatment, too. In some people, hepatitis B can reactivate when hepatitis C is treated, so the team needs a plan for hepatitis B treatment or monitoring. ³⁸

Ask one practical question: “Who is coordinating the whole plan?” You should know who checks interactions, who orders follow-up tests, and whom to call if access or side effects interrupt treatment. Coordinating several conditions and prescriptions is a real burden described in KFF Health News's reporting on aging with HIV, not a failure by the person receiving care. ¹⁶

Protect your liver without blame or “detox” promises

Hepatitis care includes discussing alcohol and reviewing new medicines or supplements before taking them. NIH advises people with chronic hepatitis B to abstain from alcohol, and hepatitis C guidance also emphasizes reducing alcohol-related liver harm. Ask for support that fits your situation rather than hiding a concern because you expect judgment. ²⁸⁴

Do not replace prescribed treatment with a supplement marketed as a cure or detox. The evidence-based treatments in this guide are vaccines where appropriate, specific antiviral medications, and follow-up care; check any added product with the care team. ¹⁸

Sterile injection equipment and access to harm-reduction services help prevent bloodborne infections. Care and treatment should remain welcoming whether someone currently uses drugs, used them in the past, or has never used them. ⁴

Symptoms and recent exposures: when to contact care

Possible hepatitis symptoms include unusual fatigue, nausea, loss of appetite, abdominal pain, dark urine, pale stools, and yellowing of the skin or eyes. Many people have no symptoms, and these symptoms can have other causes, so testing is needed rather than guessing. ¹

Contact a clinician promptly for new jaundice or a suspected exposure. After a hepatitis A exposure, the prevention window is measured in days; after a possible HIV exposure, PEP needs urgent assessment within 72 hours. These are different prevention plans for different viruses. ⁶¹⁵

If you feel severely unwell, seek urgent medical care rather than relying on this guide. For a possible recent HIV exposure, use the PEP guide and do not wait for symptoms.

Your next-visit checklist

These questions are a way to organize a visit, not a request to order every test for every person. Your clinician can tailor them to your results and history.

• My status: Have I been tested for A, B, and C, and can we review what each result means?
• My protection: Am I immune to A and B? If I completed vaccines, do I need an antibody-response check?
• My hepatitis B results: Did I have the triple panel? Does my HIV regimen cover hepatitis B if needed?
• My hepatitis C results: If antibodies were reactive, was RNA tested? If treatment is complete, when is cure being confirmed?
• My liver: Is there scarring, and do I need liver-cancer surveillance?
• My medicines: Has someone checked the complete list for interactions?
• My access: Who can help with coverage, pharmacy delays, transportation, or appointments?
• My follow-up: Which tests are due, when, and who will tell me the results?

Open the short, print-friendly hepatitis guide